Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9858173 | 1.00 | LMNA (0.72) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL4036170 | 1.00 | LMNA (0.72) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL4040051 | 1.00 | LMNA (0.72) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL14094309 | 0.94 | LMNA (0.72) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL29662067 | 0.87 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL538230 | 0.87 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL20928 | 0.87 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL8672325 | 0.87 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL14883917 | 0.86 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| Squalane SCHEMBL4708649 | 0.84 | LMNA (1.00) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088395-B2 | Phytol derived immunoadjuvants and their use in vaccine formulations | INDIANA STATE UNIVERSITY (US) | 2012-01-03 | — | — | US | claimed |
| US-20060292163-A1 | PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS | INDIANA STATE UNIVERSITY | 2006-12-28 | — | — | US | claimed |
| US-20050158329-A1 | Novel phytol derived immunoadjuvants and their use in vaccine formulations | GHOSH SWAPAN K (US) | 2005-07-21 | — | — | US | claimed |
| WO-2014089239-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-8088395-B2 | Phytol derived immunoadjuvants and their use in vaccine formulations | INDIANA STATE UNIVERSITY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20060292163-A1 | PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS | INDIANA STATE UNIVERSITY | 2006-12-28 | — | — | US | disclosed |
| US-20050158329-A1 | Novel phytol derived immunoadjuvants and their use in vaccine formulations | GHOSH SWAPAN K (US) | 2005-07-21 | — | — | US | disclosed |
| CN-1339020-A | Process for producing vitamin | DCV INC (US) | 2002-03-06 | — | — | CN | disclosed |
| CN-1330621-A | Process for producing vitamin | DCV INC (US) | 2002-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050158329-A1 | Novel phytol derived immunoadjuvants and their use in vaccine formulations | CD47, TSG101, LY96 | LMNA 3976/4885BLM 1167/4885PTPN1 475/4885 |
| US-20060292163-A1 | PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS | CD47, LY96, CD4 | LMNA 3674/4885BLM 946/4885PTPN1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.